The actions of relaxin on the human cardiovascular system-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The actions of relaxin on the human cardiovascular system

Published:2016-07-11 Issue:10 Volume:174 Page:933-949
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:British Journal of Pharmacology

Author:

Sarwar Mohsin¹,Du Xiao‐Jun²,Dschietzig Thomas B³⁴⁵,Summers Roger J¹

Affiliation:

1. Drug Discovery Biology Monash Institute of Pharmaceutical Sciences Parkville Australia

2. Baker IDI Heart and Diabetes Institute Melbourne Australia

3. Immundiagnostik AG Bensheim Germany

4. Campus Mitte, Medical Clinic for Cardiology and Angiology Charité‐University Medicine Berlin Berlin Germany

5. Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Bensheim Germany

Funder

ARC Linkage

NHMRC Programme

Zentrales Innovationsprogramm Mittelstand

BAS Medical Inc.

Publisher

Wiley

Subject

Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bph.13523

Reference169 articles.

1. Relaxin induces matrix-metalloproteinases-9 and -13 via RXFP1: Induction of MMP-9 involves the PI3K, ERK, Akt and PKC-ζ pathways

2. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes

3. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors

4. The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors

5. Relaxin Protects Rat Lungs from Ischemia-Reperfusion Injury via Inducible NO Synthase: Role of ERK-1/2, PI3K, and Forkhead Transcription Factor FKHRL1

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic potential of relaxin or relaxin mimetics in managing cardiovascular complications of diabetes;Biochemical Pharmacology;2024-11

2. Engineering and Characterization of a Long-Half-Life Relaxin Receptor RXFP1 Agonist;Molecular Pharmaceutics;2024-08-12

3. Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First‐in‐Human, Randomized, Single‐Blind, Placebo‐Controlled Study;Journal of the American Heart Association;2024-08-06

4. Relaxin as a treatment for musculoskeletal fibrosis: What we know and future directions;Biochemical Pharmacology;2024-07

5. Cardiomyocyte-specific RXFP1 overexpression protects against pressure overload-induced cardiac dysfunction independently of relaxin;Biochemical Pharmacology;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3